14 thg 9, 2026•3 phút đọc
SK Plasma launches 75 mg Revolpak, expanding dosage options for ITP and aplastic anemia
SK Plasma announced the domestic launch of Revolpak 75 mg, the first high‑dose eltrombopag product in Korea, adding to its 25 mg and 50 mg offerings for chronic immune thrombocytopenia and severe aplastic anemia.